Epidemiology of heart failure in pediatric populations in low- and middle-income countries: a protocol for a systematic review

Abstract Background Heart failure (HF) in pediatric populations is a major public health concern. It is associated with high rates of hospital admissions, disability, and mortality in high-income countries (HIC), but its burden is poorly documented in low- and middle-income countries (LMICs). We present a protocol for a systematic review and meta-analysis to summarize available data on the prevalence, incidence, etiologies, treatment, and outcomes including hospital admission and mortality and economic burden of HF in neonates, infants, children, and adolescents in LMICs. Methods A comprehensive search of articles published between January 01, 2000, and December 31, 2017, will be performed in PubMed/MEDLINE, EMBASE, Global Index Medicus, and Web of Science. All cross-sectional, cohort studies and case-control studies reporting on the prevalence, incidence, etiologies, treatment, prognosis, admission rates, mortality, and economic burden of HF in pediatric populations in LMICs will be included in the review. The methodological quality of included studies will be appraised accordingly. For prognosis data, the Quality in Prognosis Studies (QUIPS) tool will be used. The symmetry of funnel plot and Egger’s test will be used to identify publication bias. An overall summary estimate of prevalence/incidence of pediatric HF across studies will be obtained from study-specific estimates pooled through a random-effect model. Heterogeneity of studies will be assessed by the χ 2 test on Cochrane’s Q statistic. A p value less than 0.05 will be considered significant for factors that predict mortality. This systematic review and meta-analysis will be reported following the PRISMA guidelines. Discussion This study will report and summarize epidemiology data, as well as the economic burden of HF in neonates, infants, children, and adolescents of LMICs. Limitations will mainly arise from the heterogeneity in the diagnostic of HF. Systematic review registration PROSPERO CRD42017070189

Global, regional, and national prevalence of hepatitis B infection in the general and key populations living with HIV: a systematic review and meta-analysis protocol

Background: Hepatitis B causes death mainly due to liver disease worldwide. Human immunodeficiency virus increases the pathological effect of hepatitis viruses and potentiates re-activation of latent hepatitis infections as a result of reduced immunity. Because of the same modes of transmission shared by the two infections, HBV represents an important cause of co-morbidity and mortality among people living with HIV; hence, the aim of this review is to determine the prevalence of HBV among people living with HIV. Methods: This systematic review and meta-analysis will include cross-sectional, case-control, and cohort studies of patients positive for HBV and HIV irrespective of their countries. All pertinent articles published on hepatitis B in people living with HIV from January 1, 1990, to July 31, 2017, without any language restriction will be searched in PubMed/MEDLINE, Global Index Medicus Web of Science, and Excerpta Medica Database. Two review authors will independently assess the relevance of all titles and abstracts identified from the electronic searches. The study-specific estimates will be pooled through a random-effects meta-analysis model to obtain an overall summary estimate of the prevalence of HBV across studies. We will assess statistical heterogeneity and pool clinically homogeneous studies. On the other hand, we will evaluate statistical heterogeneity by the chi-squared test on Cochrane's Q statistic. Symmetry of funnel plots and Egger's test will be used to detect the presence of publication and selective reporting bias. In the case of publication bias, we will report estimates after adjustment on publication bias using the trim-and-fill method. We will assess inter-rater agreement between investigators for study inclusion, data extraction, and methodological quality assessment using Kappa Cohen's coefficient. This protocol will comply with the guidelines for meta-analyses and systematic reviews of Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA). Discussion: To our knowledge, this is the first systematic review and meta-analysis protocol to report the prevalence of HBV in people living with HIV. We believe its outcomes will be of utility in providing insights on the characteristics of HBV epidemic in people living with HIV, and draw more attention of public health services to this association. Systematic review registration: PROSPERO CRD42017073124

Data on the epidemiology of heart failure in Sub-Saharan Africa

In Sub-Saharan Africa (SSA), chronic non-communicable diseases and cardiovascular diseases in particular, are progressively taking over infectious diseases as the leading cause of morbidity and mortality. Heart failure is a major public health problem in the region. We summarize here available data on the prevalence, aetiologies, treatment, rates and predictors of mortality due to heart failure in SSA. Keywords: Heart failure, Prevalence, Aetiologies, Treatment, Mortality, Sub-Saharan Afric

Accuracy of the novel Peguero Lo‐Presti criterion for electrocardiographic detection of left ventricular hypertrophy in a black African population

Abstract The diagnostic accuracy of the electrocardiogram for left ventricular hypertrophy (LVH) is limited. Recently, Peguero and collaborators proposed a novel voltage criterion for its detection with reportedly higher accuracy than the commonly used Cornell and Sokolow‐Lyon criteria. While studies done in various populations have confirmed it, there are no available data from black African populations. We conducted a cross‐sectional study in a population from Cameroon to compare the Peguero‐Lo Presti criterion to the older Cornell, Sokolow‐Lyon, and Cornell product criteria, pertaining to their sensitivity, specificity, and area under the receiver operating characteristic curve (AUC), with echocardiography as the reference standard. The study population consisted of 238 participants (54.2% female) with a mean age of 58 (SD 13) years. On echocardiography, the prevalence of LVH was 45.3% (n = 108). The sensitivity was 48.14%, 63.89%, 63.89%, and 67.29% for the Sokolow‐Lyon, Peguero‐Lo Presti, Cornell, and Cornell product criteria, respectively. The specificity was 73.84%, 75.97%, 79.23%, and 82.31% for the Peguero‐Lo Presti, Cornell product, Cornell, and Sokolow‐Lyon criteria, respectively. The overall accuracy of the Peguero‐Lo Presti (AUC = 0.689) was not significantly different from that of the Cornell (AUC = 0.714), the Cornell product (AUC = 0.717), and the Sokolow‐Lyon (AUC = 0.652) (all p ˃ .05). Hypertension and gender influenced the agreement between ECG criteria and echocardiography in the detection of LVH. In conclusion, in this black African population, Peguero‐Lo Presti was not significantly more or less accurate than Cornell or Sokolow‐Lyon

Correlations of left ventricular systolic function indices with aortic root systolic excursion (ARSE): A cross-sectional echocardiographic study.

BACKGROUND:Heart failure (HF), is a major public health issue globally. Echocardiography is cost-effective in the diagnosis in expert hands. This study was conducted to estimate the usefulness of Aortic Root Systolic Excursion (ARSE) as a simple and accurate measure to estimate Left Ventricular (LV) function. METHODS:This was a cross-sectional echocardiographic study among adults aged ≥ 18 years, with or without heart failure, in sinus rhythm, and with no LV out-let obstruction. We studied the correlations of ARSE with some selected indices of LV Systolic Functions. We determined optimal cut-offs of ARSE in detecting LV dysfunction. We generated a simple regression equation to best estimate LV ejection fraction according to the modified Simpson method. RESULTS:Overall 213 echocardiograms were included from 106 males (49.8%), with mean age of the participants being 52.4 (SD: 18.3) years. The rate of LV systolic dysfunction was highest with Teicholz method (17.4%) and lowest with MAPSE method (5.2%). ARSE correlated with the LV functions. This was highest for the Simpson method (r = 0.619, p<0.001), and lowest for the ITV method (r = 0.319, p<0.001). Optimal cut-offs to detect LV systolic dysfunction was ≈ 6.6 mm. For an LV ejection fraction < 55%, the sensitivity was 82.9%, and the specificity was 97.2%, with an AUROC of 91.6%.The logarithmic regression equation was best in predicting LV ejection fraction (AUC: 60.2%), followed by the power model (AUC: 56.7%), and the linear model (AUC: 53.6%). CONCLUSION:ARSE correlated well with LV systolic function. The cut-off ≤ 6.5 mm suggest LV systolic dysfunction. LV Ejection Fraction was best estimated with the generic equation: LVEF (%) = 29 x In [ARSE]

Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis

Summary: Background: Although diabetes and poor glycaemic control significantly increase the risk of tuberculosis and adversely affect tuberculosis treatment outcomes, the global burden of diabetes in the context of tuberculosis remains unknown. We did a systematic review and meta-analysis to estimate the prevalence of diabetes among patients with tuberculosis at global, regional, and country levels. Methods: We searched PubMed, Excerpta Medica Database, Web of Science, and Global Index Medicus to identify studies published between Jan 1, 1986, and June 15, 2017, on the prevalence of diabetes in patients with active tuberculosis, with no language restrictions. Criteria to diagnose tuberculosis and diabetes concurred with WHO guidelines. Methodological quality of eligible studies was assessed, and random-effect models meta-analysis served to obtain the pooled prevalence estimate of diabetes among patients with active tuberculosis, globally. Heterogeneity (I2) was assessed via the χ2 test on Cochran's Q statistic. This study is registered with PROSPERO, number CRD42016049901. Findings: We screened 7565 records of which 200 studies (2 291 571 people with active tuberculosis) were included in meta-analyses. The pooled prevalence of diabetes was 15·3% (95% prediction interval 2·5–36·1; I2 99·8%), varying from 0·1% in Latvia to 45·2% in Marshall Islands. Subgroup and metaregression analyses for identifying sources of heterogeneity showed that four International Diabetes Federation (IDF) regions (North America and Caribbean [19·7%], western Pacific [19·4%], southeast Asia [19·0%], Middle East and North Africa [17·5%]) had significantly higher prevalence estimates than the three others (Africa [8·0%], South and Central America [7·7%], and Europe [7·5%]; p<0·0001). Additionally, the prevalence increased with age, in men, and in countries with low tuberculosis burden. The prevalence of diabetes was decreased in countries that had low incomes and low Human Development Index scores. The form of tuberculosis infection and presence of HIV seemed not to affect the prevalence of diabetes among patients with active tuberculosis. Interpretation: This study suggests a high burden of diabetes among patients with active tuberculosis, with disparities according to age, sex, regions, level of country income, and development. Cost-effective strategies to curb the burden of diabetes among patients with active tuberculosis are needed. Funding: None

Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis

Background Halting the rise in cardiometabolic risk factors in children and adolescents is crucial to curb the global burden of cardiovascular diseases. We aim to provide global, regional, and national estimates of the prevalence of metabolic syndrome in children and adolescents to support the development of evidence-based prevention strategies. Methods In this systematic review with modelling analysis, we searched PubMed, Embase, Africa Journal Online, and Global Index Medicus from database inception to Jan 30, 2021, with no restriction on language or geographical location. We included community-based and school-based cross-sectional studies and cross-sectional analysis of cohort studies that reported prevalence of metabolic syndrome in the general population of children (6–12 years) and adolescents (13–18 years). Only studies with a low risk of bias were considered. Eligible studies included at least 200 participants and used probabilistic-based sampling. Diagnosis of metabolic syndrome had to meet at least three of the following criteria: high systolic or diastolic blood pressure (≥90th percentile for age, sex, and height); waist circumference in at least the 90th percentile for age, sex, and ethnic group; fasting plasma glucose 5·6 mmol/L or greater; fasting plasma triglycerides 1·24 mmol/L or greater; and fasting plasma high density lipoprotein cholesterol 1·03 mmol/L or less. Independent investigators selected eligible studies and extracted relevant data. The primary outcome was a crude estimate of metabolic syndrome prevalence, assessed using a Bayesian hierarchical model. Findings Our search yielded 6808 items, of which 169 studies were eligible for analysis, including 306 prevalence datapoints, with 550 405 children and adolescents from 44 countries in 13 regions. The between-study variance (τ2) was 0·52 (95% CI 0·42–0·67), which could reflect the measurement of each component of the metabolic syndrome and covariates as sources of between-study heterogeneity. We estimated the global prevalence of metabolic syndrome in 2020 at 2·8% (95% uncertainty interval [UI] 1·4–6·7) for children and 4·8% (2·9–8·5) for adolescents, equating to around 25·8 (12·6–61·0) million children and 35·5 (21·3–63·0) million adolescents living with metabolic syndrome. In children, the prevalence of metabolic syndrome was 2·2% (95% UI 1·4–3·6) in high-income countries, 3·1% (2·5–4·3) in upper-middle-income countries, 2·6% (0·9–8·3) in lower-middle-income countries, and 3·5% (1·0–8·0) in low-income countries. In adolescents, the prevalence of metabolic syndrome was 5·5% (4·1–8·4) in high-income countries, 3·9% (3·1–5·4) in upper-middle-income countries, 4·5% (2·6–8·4) in lower-middle-income countries, and 7·0% (2·4–15·7) in low-income countries. Prevalence in children varied from 1·4% (0·6–3·1) in northwestern Europe to 8·2% (6·9–10·1) in Central Latin America. Prevalence for adolescents ranged from 2·9% (95% UI 2·6–3·3) in east Asia to 6·7% (5·9–8·3) in high-income English-speaking countries. The three countries with the highest prevalence estimates in children were Nicaragua (5·2%, 2·8–10·4), Iran (8·8%, 8·0–9·6), and Mexico (12·3%, 11·0–13·7); and the three countries with the highest prevalence estimates in adolescents were Iran (9·0%, 8·4–9·7), United Arab Emirates (9·8%, 8·5–10·3), and Spain (9·9%, 9·1–10·8). Interpretation In 2020, about 3% of children and 5% of adolescents had metabolic syndrome, with some variation across countries and regions. The prevalence of metabolic syndrome was not consistently higher with increasing level of development, suggesting that the problem is not mainly driven by country wealth. The high number of children and adolescents living with metabolic syndrome globally highlights the urgent need for multisectoral interventions to reduce the global burden of metabolic syndrome and the conditions that lead to it, including childhood overweight and obesity

Geographic distribution of metabolic syndrome and its components in the general adult population: A meta-analysis of global data from 28 million individuals

Aims Better knowledge of the global metabolic syndrome (MetS) prevalence and its components is a prerequisite to curb the related burden. Methods We systematically searched PubMed, EMBASE, Web of Knowledge, Africa Journal Online, Global Index Medicus up to May 23, 2021. Prevalence pooling was done with a random-effects meta-analysis. Results In total, 1,129 prevalence data (28,193,768 participants) were included. The MetS global prevalence varied from 12.5% (95 %CI: 10.2–15.0) to 31.4% (29.8–33.0) according to the definition considered. The prevalence was significantly higher in Eastern Mediterranean Region and Americas and increased with country’s level of income. The global prevalence was 45.1% (95 %CI: 42.1–48.2) for ethnic-specific central obesity, 42.6% (40.3–44.9) for systolic blood pressure (BP) ≥ 130 mmHg and/or diastolic BP ≥ 85 mmHg, 40.2% (37.8–42.5) for HDL-cholesterol < 1.03 for men or < 1.29 mmol/L for women, 28.9% (27.4–30.5) for serum triglycerides ≥ 1.7 mmol/L, and 24.5% (22.5–26.6) for fasting plasma glucose ≥ 5.6 mmol/L. Conclusions This study reveals that MetS and its related cardiometabolic components are highly prevalent worldwide. This study calls for more aggressive and contextualized public health interventions to tackle these conditions